A*STAR Institute of Bioengineering and Bioimaging (IBB)

Safe for human cells but toxic to bacteria, fungi and viruses, a new strategy for sanitising surfaces could give us the advantage in the fight against pathogens.

A new microfluidic liver-on-a-chip platform offers drug developers a stable, scalable and sensitive testing ground for much-needed treatments in fatty liver disease.

Researchers develop machine learning models for accurately diagnosing an inflammatory skin condition.

A new diagnostic innovation powered by artificial intelligence could empower surgeons to make more accurate and effective clinical decisions for colon cancer patients.

Harnessing the different properties of light could help researchers and clinicians develop bio-optical medical innovations, says A*STAR Senior Scientist Renzhe Bi.

Imaging experts discover a non-invasive method to identify which patients with liver cancer are most likely to respond to immunotherapy.

To fully realise the potential of medical technology, A*STAR scholar Daryl Jude Lawrence explains why scientists should move beyond the lab and experience the inner workings of industry-level production and entrepreneurship.

Game-changing new ideas and products are born from connecting the right minds and hands. In this cover story, we spotlight how A*STAR facilitates those connections and cultivates the culture needed for an ecosystem of innovation.

Non-invasive imaging technology reveals how radiation exposure in the brain, particularly early in life, damages delicate brain tissue.

A head-to-head test of three common mask decontamination methods helps frame standardised national guidelines.

New self-cleaning surfaces created by A*STAR researchers take inspiration from cicada wings to attract and destroy microbes without harsh chemicals.

Synthetic DNA molecules could serve as an easy-to-manufacture alternative to traditional antibody-based rapid tests.